Gilteritinib 40 MG Oral Tablet + Cladribine + Cytarabine + Filgrastim + Mitoxantrone
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Mar 1, 2023 → May 30, 2032
NCT ID
NCT05330377About Gilteritinib 40 MG Oral Tablet + Cladribine + Cytarabine + Filgrastim + Mitoxantrone
Gilteritinib 40 MG Oral Tablet + Cladribine + Cytarabine + Filgrastim + Mitoxantrone is a phase 1 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05330377. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05330377 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Acute Myeloid Leukemia